Online inquiry

IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2894MR)

This product GTTS-WQ2894MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17RA gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001289905.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23765
UniProt ID Q96F46
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2894MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9537MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ16007MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ5084MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ9169MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ4176MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ4013MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ6214MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CR4098
GTTS-WQ8775MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-306
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW